Your Brain On Cancer
Once you enter cancerland, your brain takes detours all the time. Where do these detours go? BAD PLACES!" Is that a zit? No, of course not. Its a tumor. Must be skin cancer. "" A headache? No, a brain tumor. Dead in 3 months. "" Is that a swollen lymph node? Quick, leukemia or lymphoma, which one? "As you can easily see you brain with cancer goes down the wrong roads. Usually in the middle of the night. Or when your are stuck in traffic by yourself.You start making little deals with yourself. " I'll wait a month and see if its still a problem. No, a month? No three weeks. Wait, two weeks. Maybe ten days. Do I have any blood work coming up? Maybe that will tell me something. "" Wait, am I a lunatic? Actually thinking like this will turn me into a lunatic! "The big thing is to learn to control your brain so it doesn't take all the detours. That is the really hard part of living with cancer. Your brain develops a this ability to drive you crazy and lead you into bad places. You need to get it under control so you can keep your sanity and avoid things like depression and anxiety.Its a lifelong problem. It will never go away. Such is cancerland.
This article discusses the characterization with theoretical and experimental basis of Vismodegib, providing a thorough insight knowledge of the drug itself. The energy of the structure was minimized employing a commercial code, and different approaches were used to determine the bond distances and hyperconjugative interactions. The information obtained by theoretical calculation was correlated with experimental data of vibrational spectroscopies: FTIR and Raman. The main vibrational modes were theoretically evaluated and correlated with experimental data.Graphical abstract
In this study, miR-101 expression was markedly downregulated in the OSCC cell lines and tissues. CCK-8, EdU, and colony formation assays showed that miR-101 inhibited the proliferation of OSCC cells. Flow cytometry and caspase-3 activity assays indicated that miR-101 induced OSCC cell apoptosis. Transwell assays demonstrated that this miRNA also repressed OSCC cell migration and invasion. Moreover, tube formation assay showed that miR-101 abated the pro-angiogenesis of OSCC cells. Dual luciferase reporter assay confirmed that miR-101 directly targeted TGF-βR1 in OSCC. Ectopic expression of TGF-βR1 counteracted th...
ConclusionsOur findings provide preliminary evidence that resting-state functional connectivity can characterize depressed PD patients and help distinguish them from non-depressed ones.
ConclusionThe lower involvement of brain regions observed in Takotsubo patients suggests an impairment in emotional regulation, which might be of etiological importance in this brain-heart disease.
CONCLUSIONS: T3b, distinguished from minimal ETE, may be related to larger tumor size, higher prevalence of multifocality, LNM, DM, recurrence and worse RFS than no ETE, but it may not affect OS and may not independently predict recurrence in PTC patients. PMID: 31830859 [PubMed - as supplied by publisher]
CONCLUSIONS: The clinical content and evidence explanations in the adult thyroid nodule and differentiated thyroid cancer CPG are widely accepted and applied among ATA survey respondents. Future ATA CPG updates need to be optimized to best meet users' preferences regarding format, frequency and length. PMID: 31830853 [PubMed - as supplied by publisher]
Publication date: Available online 14 December 2019Source: Social Science &MedicineAuthor(s): Catherine Bourgain, Lionel Pourtau, Chafika Mazouni, Martine Bungener, et Julia Bonastre
In this study, we investigate, in vitro, whether miRNA-593-5p inhibits NSCLC cell proliferation. To clarify its specific mechanism of inhibition, we used bioinformatics to predict its target genes and identified PLK1. Luciferase reporter assay confirmed the binding of miR-593-5p to the PLK1 3’-UTR in a sequence-specific manner in NSCLC cells. Additionally, we also found through Western blot and quantitative RT-PCR that miR-593-5p down-regulates the expression of PLK1 protein. Finally, PLK1 overexpression was shown to disinhibit NSCLC cell proliferation. Taken together, this evidence suggests that miR-593-5p inhibits ...
Authors: de Arriba-Arnau A, Soria V, Salvat-Pujol N, Menchón JM, Urretavizcaya M Abstract There is a lack of research regarding 0.5-ms pulse width (PW) in bilateral electroconvulsive therapy (ECT). The aim of this study was to compare the efficacy and number of treatment sessions between groups receiving 0.5-ms and 1-ms PW ECT. Ninety-four patients with unipolar major depression treated with acute bilateral ECT were analysed retrospectively, grouped as consecutive patients treated with 0.5-ms PW ECT (n = 47), and age- and sex-matched patients treated with 1-ms PW ECT. Clinical and ECT data were...
Reuters Health Information